Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The American Urological Association (AUA) and Society of Urologic Oncology (SUO) have released a sweeping 2026 update to their non-muscle invasive bladder cancer (NMIBC) guidelines. The amendment adds 40 new recommendations covering risk stratification, biomarkers, and bladder-preserving therapies. For select patients with recurrent low-grade disease, active surveillance and chemoablation are now on the table as alternatives to surgery.
The AUA and SUO have jointly released a 2026 amendment to their NMIBC guidelines, marking one of the most comprehensive updates to bladder cancer management in recent years. The revision introduces 40 new recommendations and touches nearly every aspect of care — from how patients are risk-stratified to how they're monitored and treated. NMIBC represents about 80% of all newly diagnosed bladder cancer cases in the U.S., making these updates broadly impactful for urologists and oncologists alike.
A standout addition is the formal recognition of bladder-preserving strategies — including active surveillance, office-based treatment, and chemoablative therapy — for select patients with recurrent low-grade disease. This could meaningfully reduce the number of patients undergoing operative interventions. The amendment also expands guidance on urinary biomarkers, enhanced cystoscopy, BCG maintenance, and management of BCG-unresponsive disease, including options for high-risk cases involving the prostatic urethra.
By the Numbers:
Why it matters: With NMIBC accounting for the vast majority of bladder cancer diagnoses, these updated guidelines give clinicians a more nuanced, evidence-based roadmap for individualizing care — potentially sparing some patients from surgery while ensuring high-risk cases receive appropriately aggressive management.
